Organic compounds

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

Retrieved on: 
Wednesday, July 14, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Clinical medicine, Brand management, Brands, Intellectual property law, Product management, Trademark, Mitomycin C, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UROGEN PHARMA LTD.

Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 to $38 million.

Key Points: 
  • Additionally, operating expenses in the second quarter of 2021 are anticipated to be in the range of $33 to $38 million.
  • We look forward to reporting our full results for the second quarter of 2021 in early August.
  • The Company expects to report full financial results for the second quarter ended June 30, 2021, and host a conference call on Wednesday, August 4, 2021.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005260/en/

Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union

Retrieved on: 
Wednesday, July 14, 2021
Chemical compounds, Basilea Pharmaceutica, Heterocyclic compounds, Organic compounds, Ceftobiprole

53 LR

Key Points: 
  • 53 LR
    Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basileas antibiotic Zevtera (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union.
  • In addition, Basilea will receive an upfront payment and be eligible for sales milestone payments.
  • David Veitch, Chief Executive Officer, stated: "We are pleased to extend our commercial partnerships for Zevtera to Russia and other Eurasian countries.
  • JSC Lancet is a leading hospital products company and one of the fastest growing pharmaceutical companies in Russia.

CGF Plastic Waste Coalition Launches Full Set of "Golden Design Rules" to Tackle Plastic Waste

Retrieved on: 
Tuesday, July 13, 2021
Organic polymers, Containers, Organic compounds, Labels, Packaging and labeling, Product management, Plastic container, Plastic, High-density polyethylene, Loblaw Companies, Materials

Advancing on their first priority, Coalition members have now finalised the complete series of "Golden Design Rules" , for the design of plastic packaging, created to accelerate progress towards using less and better plastic.

Key Points: 
  • Advancing on their first priority, Coalition members have now finalised the complete series of "Golden Design Rules" , for the design of plastic packaging, created to accelerate progress towards using less and better plastic.
  • The latest design rules focus on eliminating unnecessary plastic packaging, by reducing headspace and plastic overwraps, as well as increasing recycling value in various types of plastic, including PET thermoformed packaging, flexible consumer packaging and rigid HDPE and PP.
  • Business-to-business plastic packaging will also be targeted, with the elimination of all unnecessary packaging that doesn't reach the consumer.
  • The Coalition is sponsored at the CGF Board level by Alan Jope, CEO, Unilever, and Galen Weston, Executive Chairman, Loblaw Companies Limited.

CGF Plastic Waste Coalition Launches Full Set of "Golden Design Rules" to Tackle Plastic Waste

Retrieved on: 
Tuesday, July 13, 2021
Organic polymers, Containers, Organic compounds, Labels, Packaging and labeling, Product management, Plastic container, Plastic, High-density polyethylene, Loblaw Companies, Materials

Advancing on their first priority, Coalition members have now finalised the complete series of "Golden Design Rules" , for the design of plastic packaging, created to accelerate progress towards using less and better plastic.

Key Points: 
  • Advancing on their first priority, Coalition members have now finalised the complete series of "Golden Design Rules" , for the design of plastic packaging, created to accelerate progress towards using less and better plastic.
  • The latest design rules focus on eliminating unnecessary plastic packaging, by reducing headspace and plastic overwraps, as well as increasing recycling value in various types of plastic, including PET thermoformed packaging, flexible consumer packaging and rigid HDPE and PP.
  • Business-to-business plastic packaging will also be targeted, with the elimination of all unnecessary packaging that doesn't reach the consumer.
  • The Coalition is sponsored at the CGF Board level by Alan Jope, CEO, Unilever, and Galen Weston, Executive Chairman, Loblaw Companies Limited.

Polyamide Market Size is Projected To Reach USD 40.6 Billion By 2028, Growing at a CAGR of 5.4% - Valuates Reports

Retrieved on: 
Monday, July 12, 2021
Organic compounds, Dielectrics, Polymers, Chemistry, Polyamide, Thermoplastics, Poly

The global Polyamide Market size was valued at USD 26.7 Billion in 2020 and is projected to reach USD 40.6 Billion by 2028, growing at a CAGR of 5.4% from 2021 to 2028.

Key Points: 
  • The global Polyamide Market size was valued at USD 26.7 Billion in 2020 and is projected to reach USD 40.6 Billion by 2028, growing at a CAGR of 5.4% from 2021 to 2028.
  • The increasing use of polyamide in automobiles is driving the growth of polyamide market size.
  • Over the projected period, the rising electrical and electronics industry is likely to increase the growth of the polyamide market size.
  • Furthermore, due to an increase in automotive and food packaging applications, Asia-Pacific has emerged as a prominent regional polyamide market.

Worldwide Polyvinyl Chloride Industry Outlook to 2025 - Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Chemicals, Plastics, Manufacturing, Commodity chemicals, Organic compounds, Goods economics), Chemistry, Dielectrics, Monomers, Vinyl chloride, Polyvinyl chloride

The "Global Polyvinyl Chloride Industry Outlook to 2025 - Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Polyvinyl Chloride Industry Outlook to 2025 - Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants" report has been added to ResearchAndMarkets.com's offering.
  • Among countries, China is expected to lead Polyvinyl Chloride capacity additions by 2025, followed by India and the US.
  • Asia Polyvinyl Chloride Industry, Annual New Build and Expansion Capital Expenditure Outlook for Active, Planned and Announced Projects
    4.5.
  • Asia Polyvinyl Chloride Industry, Annual New Build and Expansion Capital Expenditure Outlook for Active, Planned and Announced Plants by Countries
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005472/en/

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Nucleic acids, RNA, DNA, Molecular biology, OPKO Health, Organic compounds, Sense, Oligonucleotide, Organic polymers, Cis-natural antisense transcript

MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA.

Key Points: 
  • MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA.
  • AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein.
  • Under the terms of the agreement, OPKO will receive an upfront payment and shares of CAMP4.
  • CAMP4 is pioneering a novel approach to programmable therapeutics that combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality.

Styrene Global Market Report 2021: COVID-19 Impact and Recovery to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Chemicals, Plastics, Manufacturing, Organic polymers, Organic compounds, Chemistry, Commodity chemicals, Copolymers, Thermoplastics, Plastics, Styrene, Polystyrene, Acrylonitrile butadiene styrene, Acrylonitrile styrene acrylate

The "Styrene Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Styrene Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Styrene Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global Styrene market as it emerges from the COVID-19 shut down.
  • The styrene market consists of sales of styrene and related services used for making synthetic rubber, resins, and plastics and improving drying oils.
  • The styrene market covered in this report is segmented by type: acrylonitrile butadiene styrene, expanded polystyrene, others.

Tricor Group Signs a Sale and Purchase Agreement to Acquire NZGT Holding Company Limited Expanding Corporate Trust Business and Broadening APAC Footprint Covering New Zealand

Retrieved on: 
Monday, July 12, 2021
Chemistry, Offshore finance, Trust company, Organic compounds, Corporate trust, Fenofibrate, Chemical compounds

HONG KONG, July 12, 2021 /PRNewswire/ -- Tricor Group (Tricor), Asia's leading business expansion specialist, has signed a sale and purchase agreement to acquire NZGT Holding Company Limited (NZGT Holdings)together with its wholly owned subsidiaries The New Zealand Guardian Trust Company Limited (Guardian Trust) and Covenant Trustee Services Limited (Covenant) from Complectus Limited.

Key Points: 
  • HONG KONG, July 12, 2021 /PRNewswire/ -- Tricor Group (Tricor), Asia's leading business expansion specialist, has signed a sale and purchase agreement to acquire NZGT Holding Company Limited (NZGT Holdings)together with its wholly owned subsidiaries The New Zealand Guardian Trust Company Limited (Guardian Trust) and Covenant Trustee Services Limited (Covenant) from Complectus Limited.
  • Tricor is the largest pure-play corporate services platform in APAC, serving over 50,000 client entities across its 21-market footprint.
  • Tricor's Global Corporate Trust business will operate and serve clients across 5 global markets including Hong Kong SAR, Beijing, Singapore, UK and New Zealand.
  • The addition of Guardian Trust and Covenant to Tricor's corporate trust business practice will enable us to enhance our client proposition and offer market-leading trust solutions in New Zealand and across Australasia and Asia-Pacific."

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Exelixis, Cyclopropanes, Quinolines, Cabozantinib, Cobimetinib, Daiichi Sankyo, NASDAQ

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.